UMIN ID: UMIN000001632
Registered date:14/01/2009
Vaccination trial with the PBF-derived peptide in HLA-A2+ patients with osteosarcoma
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | osteosarcoma |
Date of first enrollment | 2009/01/01 |
Target sample size | 20 |
Countries of recruitment | Japan |
Study type | Interventional |
Intervention(s) | HLA-A2-restricted PBF peptide(ALPSFQIPV) 1mg IFA HLA-A2-restricted PBF peptide(ALPSFQIPV) 10mg +IFA HLA-A2-restricted PBF peptide(ALPSFQIPV) 1mg +IFA +Interferon alpha HLA-A2-restricted PBF peptide(ALPSFQIPV) 10mg +IFA +Interferon alpha |
Outcome(s)
Primary Outcome | Toxicity, immunological response, anti-tumor effects |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | 10years-old |
---|---|
Age maximum | 70years-old |
Gender | Male and Female |
Include criteria | |
Exclude criteria | Exclusion criteria included (i) prior chemotherapy, steroid therapy, or other immunotherapy within the past 4 weeks, (ii) presence of severe organ failure or other cancers that might influence the prognosis, (iii) immunodeficiency or a history of splenectomy, (iv) severe cardiac insufficiency, acute infection, or hematopoietic failure, (v) pregnany or ongoing breast-feeding, (vi) unsuitability for the trial based on the clinical judgment of the doctors involved. |
Related Information
Primary Sponsor | Dept Orthopaedic Surgery, Sapporo Medical University |
---|---|
Secondary Sponsor | Dept Pathology, Sapporo Medical University |
Source(s) of Monetary Support | Grants-in-Aid from MEXT, the Ministry of Health, Labor and Welfare. |
Secondary ID(s) |
Contact
public contact | |
Name | Takuro Wada |
Address | Japan |
Telephone | |
twada@sapmed.ac.jp | |
Affiliation | Sapporo Medical University Department of Orthopaedic Surgery |
scientific contact | |
Name | Takuro Wada |
Address | South-1, West-16, Chuo-ku, Sapporo Japan |
Telephone | |
Affiliation | Sapporo Medical University Department of Orthopaedic Surgery |